RECRUITING

Targeted Transcranial Magnetic Stimulation to Improve Hippocampal-dependent Declarative Memory Abilities

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This is a pilot study of non-invasive transcranial magnetic stimulation (TMS) to improve memory in healthy adults. It will also examine treating memory deficits in older adults with amnestic mild cognitive impairment (aMCI), a condition that frequently precedes Alzheimer's disease (AD). The study will test whether a form of non-invasive brain stimulation repetitive transcranial magnetic stimulation (rTMS) can improve memory abilities in healthy young adults, healthy older adults, and older adults with aMCI by retuning memory-related brain networks. This study is a key first step which will support the long-term goal of treating memory deficits in neurological patients. It is expected that rTMS will improve memory abilities in all participants, and that the improvements in memory will be attributable to changes in the connectivity of memory-related brain networks.

Official Title

Targeted Transcranial Magnetic Stimulation to Improve Hippocampal-dependent Declarative Memory Abilities

Quick Facts

Study Start:2019-01-01

Study Completion:2026-12

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT03574207

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:19 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:Yes

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Adults 19 years of age and older 2. Healthy adults without history of psychiatric or neurological disease OR previous diagnosis of amnestic MCI 3. Must be able to provide informed consent 4. Must have the ability to comply with basic instructions and have the ability to sit comfortably still for TMS, neuroimaging, and other study procedures. 5. Right-handed based on self-report (pre-screening) and evaluation with a standard test.	1. Individuals who have ferrous metal implanted in their body (other than in their teeth) or any other non-removable medical and/or metallic implant 2. Individuals who have increased intracranial pressure 3. Individuals who have any major medical illness (e.g., cancer, HIV+, hepatitis, heart disease) 4. Individuals who have confounding/dual diagnoses (e.g., comorbid mental illness and substance use disorder) 5. Individuals with current diagnoses of alcohol or substance abuse/dependence 6. Individuals with epilepsy, any history of seizures, or using medication that lowers seizure threshold 7. Individuals with any neurological disorder other than aMCI (e.g., stroke, traumatic brain injury) 8. Pregnant females --- as determined by urine pregnancy test --- will be excluded from this study due to uncertainty of the effects of MRI and TMS on the fetus 9. Not right-handed based on self-report (pre-screening) or evaluation with a standard test 10. Not a native English speaker.

Inclusion Criteria

Exclusion Criteria

1. Adults 19 years of age and older
2. Healthy adults without history of psychiatric or neurological disease OR previous diagnosis of amnestic MCI
3. Must be able to provide informed consent
4. Must have the ability to comply with basic instructions and have the ability to sit comfortably still for TMS, neuroimaging, and other study procedures.
5. Right-handed based on self-report (pre-screening) and evaluation with a standard test.

1. Individuals who have ferrous metal implanted in their body (other than in their teeth) or any other non-removable medical and/or metallic implant
2. Individuals who have increased intracranial pressure
3. Individuals who have any major medical illness (e.g., cancer, HIV+, hepatitis, heart disease)
4. Individuals who have confounding/dual diagnoses (e.g., comorbid mental illness and substance use disorder)
5. Individuals with current diagnoses of alcohol or substance abuse/dependence
6. Individuals with epilepsy, any history of seizures, or using medication that lowers seizure threshold
7. Individuals with any neurological disorder other than aMCI (e.g., stroke, traumatic brain injury)
8. Pregnant females --- as determined by urine pregnancy test --- will be excluded from this study due to uncertainty of the effects of MRI and TMS on the fetus
9. Not right-handed based on self-report (pre-screening) or evaluation with a standard test
10. Not a native English speaker.

Contacts and Locations

Study Contact

Anna Wilhelm, MA

CONTACT

402-559-5805

wnl@unmc.edu

Principal Investigator

David E Warren, PhD

PRINCIPAL_INVESTIGATOR

University of Nebraska

Study Locations (Sites)

University of Nebraska Medical Center

Omaha, Nebraska, 68198

United States

Collaborators and Investigators

Sponsor: University of Nebraska

David E Warren, PhD, PRINCIPAL_INVESTIGATOR, University of Nebraska

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-01-01

Study Completion Date2026-12

Study Record Updates

Study Start Date2019-01-01

Study Completion Date2026-12

Terms related to this study

Additional Relevant MeSH Terms

Mild Cognitive Impairment
Memory Loss